LOC729086: A Potential Drug Target and Biomarker for Overexpressed Prosurvival Protein 1 Pseudogene in Cancer

Target Name: LOC729086

NCBI ID: G729086

LOC729086

Other Name(s): Vesicular, overexpressed in cancer, prosurvival protein 1 pseudogene | VOPP1, WBP1/VOPP1 family member pseudogene

LOC729086: A Potential Drug Target and Biomarker for Overexpressed Prosurvival Protein 1 Pseudogene in Cancer

Prosurvival protein 1 (PSP1) is a protein that has been shown to play a crucial role in cancer cell survival and proliferation. The overexpression of PSP1 has been identified as a common event in many types of cancer, and as a potential drug target in cancer treatment. LOC729086 is a specific pseudogene for PSP1 that has been identified as an overexpressed gene in various types of cancer. In this article, we will discuss the potential implications of LOC729086 as a drug target and biomarker for cancer.

The Importance of Prosurvival Protein 1

PSP1 is a 21-kDa protein that is expressed in various tissues, including the brain, heart, and gastrointestinal tract. It is known to play a role in cell survival and proliferation by promoting the formation of a protein complex called Bcl-2/p53. This complex helps to prevent apoptosis, which is a mechanism by which cells are able to detect and respond to environmental stressors, such as UV radiation or radiation therapy.

The overexpression of PSP1 has been identified as a common event in many types of cancer. For example, overexpression of PSP1 has been shown to contribute to the development and progression of breast cancer. In addition, overexpression of PSP1 has also been shown to contribute to the development and progression of other types of cancer, including lung cancer, colon cancer, and pancreatic cancer.

The Potential Role of LOC729086 as a Drug Target

LOC729086 is a specific pseudogene for PSP1 that has been identified as an overexpressed gene in various types of cancer. It is located on chromosome 7 and encodes a protein with 21 amino acid residues. LOC729086 is expressed in various tissues, including the brain, heart, and gastrointestinal tract, and has been shown to play a role in cell survival and proliferation.

In cancer treatment, targeting PSP1 directly or indirectly through modifying its expression levels can be an effective way to inhibit cancer cell growth and proliferation. One potential approach to targeting PSP1 is to target its downstream target, Bcl-2. Bcl-2 is a protein that has been shown to interact with PSP1 and can modulate its activity.

Studies have shown that LOC729086 is overexpressed in various types of cancer, including breast cancer, lung cancer, and colon cancer. Additionally, studies have shown that LOC729086 is able to bind to Bcl-2 and can inhibit its activity. This suggests that LOC729086 may be an effective drug target for cancer treatment by targeting Bcl-2 and inhibiting its activity.

The Potential Role of LOC729086 as a Biomarker

In addition to its potential as a drug target, LOC729086 may also be an effective biomarker for cancer. As mentioned earlier, LOC729086 is an overexpressed gene in various types of cancer, and its expression levels can be used as a indicator of disease status. For example, lower levels of LOC729086 may indicate the presence of cancer, while higher levels may indicate the presence of cancer recurrence.

In addition to its potential as a biomarker, LOC729086 may also be used as a target for diagnostic tests for cancer. For example, if LOC729086 is overexpressed in a particular type of cancer, it may be possible to use PCR or other molecular techniques to detect its expression in cancer tissue. This could provide a sensitive and accurate method

Protein Name: VOPP1, WBP1/VOPP1 Family Member Pseudogene

The "LOC729086 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC729086 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets